Axsome Therapeutics Files 8-K Report
Ticker: AXSM · Form: 8-K · Filed: Jan 31, 2025 · CIK: 1579428
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: AXSM
TL;DR
AXSM filed an 8-K, likely with financial updates. Keep an eye out for details.
AI Summary
On January 30, 2025, Axsome Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant business events. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Axsome Therapeutics is providing updated information to the SEC, which could include material business developments or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report, and the provided excerpt does not contain information indicating significant new risks.
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- 0000950170-25-011220 (other) — Accession Number
- January 30, 2025 (date) — Date of earliest event reported
- One World Trade Center, 22nd Floor, New York, New York 10007 (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Axsome Therapeutics?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant business events.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is January 30, 2025.
What is Axsome Therapeutics' principal executive office address?
The address is One World Trade Center, 22nd Floor, New York, New York 10007.
What is the Commission File Number for Axsome Therapeutics?
The Commission File Number is 001-37635.
What is the IRS Employer Identification Number for Axsome Therapeutics?
The IRS Employer Identification Number is 45-4241907.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 9.8 · Accepted 2025-01-30 17:55:27
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market
Filing Documents
- axsm-20250130.htm (8-K) — 43KB
- axsm-ex99_1.htm (EX-99.1) — 72KB
- img36028404_0.jpg (GRAPHIC) — 65KB
- 0000950170-25-011220.txt ( ) — 325KB
- axsm-20250130.xsd (EX-101.SCH) — 23KB
- axsm-20250130_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On January 30, 2025, Axsome Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO for the acute treatment of migraine with or without aura in adults. The full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 30, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: January 30, 2025 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer